CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 376 enrolled
Drug / intervention
Clopidogrel +3 moredrug
Likely dose
Clopidogrel 300mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04824911
NCT04824911Phase 2Completed
CompareCT.gov

Early Intensive Medical Therapy for the Prevention of Early Neurological Deterioration in Branch Atheromatous Disease

Chang Gung Memorial Hospital·interventional·Posted Apr 1, 2021·Updated Mar 26, 2025

In Brief

A Phase 2 clinical trial evaluating Clopidogrel, Aspirin, and 2 other interventions for Acute Stroke and 2 related conditions. Completed, enrolled 376 participants across 1 site.

Detailed Summary

Branch atheromatous disease (BAD) has been reported to contribute to small-vessel occlusion and is associated with a higher possibility of early neurological deterioration (END). Because the pathology of BAD is due to atherosclerosis, the investigators postulate that early intensive medical treatment with dual antiplatelet therapy(DAPT) and high-intensity statin may prevent END and recurrent stroke. The investigators hypothesise that intensive medical therapy can prevent END in BAD using aspirin, clopidogrel and high-intensity statin.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Stroke, Dual Antiplatelet Therapy, Statin
CountriesTaiwan
Collaborators--

Timeline

Phase 2CompletedFinished
20222023202420252026
First PostedApr 1, 2021
Enrollment StartMar 23, 2021
Primary CompletionFeb 28, 2025
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 5.3 years ago

Interventions

Clopidogreldrug

300mg loading and 75mg/day from day 2

Aspirindrug

Aspirin(100-300mg/day)

Atorvastatindrug

Atorvastatin 40-80mg/day

Rosuvastatindrug

Rosuvastatin 20 mg/day.